US NHL Cases/Year
~80,000
Most common hematologic malignancy in the US, encompassing dozens of histologic subtypes from indolent follicular to aggressive DLBCL.[1]
What Is It
Definition, mechanism, and the clinical reality of lymphoma at end of life. What the hospice team needs to understand on day one.
US Hodgkin Lymphoma Cases/Year
~8,500
Most curable lymphoma; 5-year survival >85% overall. Patients who reach hospice have exhausted multiple curative lines.[2]
DLBCL Refractory Rate
~30–40%
Of DLBCL patients, 30–40% do not achieve durable remission or relapse early — this population defines the majority of lymphoma hospice referrals.[3]
CAR-T Response Rate
~50% CR
~50% complete response in refractory DLBCL — but half of responders relapse; post-CAR-T relapse has very poor prognosis (median OS 3–5 months).[4]
Lymphoma is not one disease. It is dozens of diseases organized under one name by the fact that they arise from lymphocytes. Non-Hodgkin lymphoma encompasses more than 80 recognized subtypes — from indolent follicular lymphoma that waxes and wanes for a decade to double-hit diffuse large B-cell lymphoma that kills within months. Hodgkin lymphoma, though rarer, is among the most curable cancers in medicine — which means the patients who reach hospice have typically exhausted every curative option including brentuximab vedotin, checkpoint inhibitors, and often autologous stem cell transplant.[1][2]
At end of life, what is consistent across all lymphoma subtypes: the disease is often visually dramatic (massive lymph nodes, drenching sweats, obstructed airways), the treatment history is long and complex (often 3–5+ lines of therapy including novel agents and CAR-T), and patients frequently arrive on hospice having just been told there was one more thing to try. CAR-T cell therapy has fundamentally changed the end-of-life landscape — patients now arrive post-CAR-T with immune reconstitution failure, cytokine release syndrome sequelae, and families who were told a cure was possible.[4][5]
🧭 Clinical framing
Lymphoma hospice is defined by two realities that exist simultaneously and in tension: the disease is often visually dramatic — massive lymph nodes, drenching sweats, obstructed airways — while the patient may be receiving or recently completed therapies that families believe were working. The hospice clinician must meet that grief without dismissing it. Every conversation begins by understanding what the patient and family were told — and whether the treatment they expected to work was CAR-T cell therapy, bispecific antibodies, or one of the dozens of other options in the modern lymphoma armamentarium.
"Lymphoma is the diagnosis where the family walks in with a three-inch-thick binder of treatment records and a story that ends with 'and then they said there was nothing left.' Except there was something left — the CAR-T that didn't hold, the bispecific that bought three months, the clinical trial that closed. Your first job is not to explain hospice. Your first job is to read that binder, understand what they've been through, and acknowledge that every single one of those treatments represented real hope. Then you can talk about what comes next."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Excisional lymph node biopsy: Gold standard — core needle biopsy acceptable but excisional preferred for architecture assessment and adequate tissue for full immunohistochemistry panel[6]
- CT chest-abdomen-pelvis with contrast: Staging; PET-CT most sensitive for staging and response assessment using Deauville score[7]
- Bone marrow biopsy: Bilateral trephine biopsies for staging; involvement changes stage and sometimes treatment approach
- Flow cytometry: Peripheral blood — if circulating lymphoma cells suspected
- Immunohistochemistry panel: CD20, CD10, BCL2, BCL6, MYC, MUM1, Ki-67 proliferation index — defines DLBCL subtype (GCB vs ABC/non-GCB); dual expressor vs double-hit vs triple-hit[8]
- FISH for MYC, BCL2, BCL6 rearrangements: Double-hit/triple-hit lymphoma = very aggressive, worst prognosis in DLBCL[9]
- Lumbar puncture: CNS staging in high-risk DLBCL — CNS IPI score determines prophylaxis need
- Ann Arbor staging with Lugano modification: Stage I–IV; A = no B symptoms, B = B symptoms present[7]
What to Look for in Hospice Records
- Histologic subtype: DLBCL vs follicular vs marginal zone vs MCL vs T-cell lymphoma vs Hodgkin — each has different trajectory and management
- Double-hit/triple-hit status: Worst prognosis in DLBCL — MYC + BCL2 and/or BCL6 rearrangements[9]
- Transformation history: Follicular transforming to DLBCL, CLL transforming to DLBCL as Richter transformation — marks a prognostic inflection point[10]
- CAR-T therapy history: Which product (axi-cel, tisa-cel, liso-cel), when administered, response duration, current immune reconstitution status — hypogammaglobulinemia from B-cell aplasia persists for months to years post-CAR-T[4]
- Prior CNS involvement: CNS lymphoma relapse has very poor prognosis
- Current B symptom status and steroid dose/duration: Steroids are frequently used for symptom control even in end-stage disease — dependency and taper planning are primary clinical tasks
💡 B symptoms — know the definition precisely
B symptoms defined precisely: unexplained fever >38°C, drenching night sweats requiring linen change, unexplained weight loss >10% body weight in 6 months. B symptoms at diagnosis define higher stage and worse prognosis. B symptoms at end-stage define one of the most physically distressing symptom complexes in all of hospice — and they are clinically manageable with dexamethasone, NSAIDs, and in some cases palliative rituximab.[11]
Causes & Risk Factors
Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
NHL Risk Factors
- Immune suppression: HIV/AIDS (60x increased risk of aggressive NHL), solid organ transplant recipients (PTLD), primary immune deficiencies[12]
- EBV infection: Burkitt lymphoma, post-transplant lymphoma, HIV-associated lymphoma — EBV drives lymphomagenesis in immune-compromised hosts[13]
- H. pylori infection: Gastric MALT lymphoma — H. pylori eradication can cure localized gastric MALT[14]
- Hepatitis C: Splenic marginal zone lymphoma and some DLBCL — antiviral treatment can induce lymphoma remission[15]
- Autoimmune conditions: Sjögren syndrome (marginal zone), Hashimoto thyroiditis (thyroid MALT), celiac disease (enteropathy-associated T-cell lymphoma)[16]
- Occupational exposures: Pesticides (herbicides, particularly glyphosate), hair dye, benzene, Agent Orange in veterans[17]
- Prior chemotherapy/radiation therapy: Therapy-related lymphoma
Hodgkin Lymphoma & Non-Modifiable
- EBV infection: 30–40% of classical Hodgkin is EBV-positive; distinct biology and checkpoint inhibitor response[13]
- Bimodal age distribution: Peak ages 15–30 and again after 55[2]
- Male sex, HIV infection: HIV-positive HL presents at advanced stage[12]
- Family history: Modest increased risk in first-degree relatives
❤️ For families: "Why did this happen?"
Most lymphomas arise without an identifiable cause. Your loved one did not do anything wrong. In some cases, viral infections (like EBV), immune suppression, or environmental exposures played a role — but even in those cases, the person could not have known or prevented it. The disease arose from the immune system itself — the very cells designed to protect the body.
⚕ Clinician note: Disparities in lymphoma care
HIV-associated lymphoma disproportionately affects Black Americans and Hispanic Americans who have less access to HIV treatment and thus higher rates of AIDS-defining malignancies. Black Americans with DLBCL have lower rates of CAR-T referral and utilization despite similar disease characteristics — a documented access disparity in one of the most promising curative therapies. Hodgkin lymphoma in HIV-positive patients and in Hispanic Americans tends to present at more advanced stage with worse outcomes.[18]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Lymphoma treatment is among the most complex in oncology. Patients arriving on hospice may have received 3–7 lines of therapy over years. Understanding what they received — and what it did to their body — is essential for hospice management. The regimens below represent the standard treatment trajectory; your patient has likely been through several of these.[19]
First-Line & Salvage Therapy
- DLBCL first-line: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone — 6 cycles; ~60% cure rate); Pola-R-CHP (POLARIX trial; improved PFS)[19][20]
- Salvage: R-ICE, R-DHAP, R-GDP (platinum-based salvage — bridge to ASCT); Autologous stem cell transplant (ASCT — consolidation in chemosensitive relapse)[21]
- CAR-T cell therapy: axi-cel/Yescarta, tisa-cel/Kymriah, liso-cel/Breyanzi — approved for DLBCL after ≥2 lines; ZUMA-7 and TRANSFORM trials showed superiority over ASCT in early relapse[4][22]
- Bispecific antibodies: epcoritamab, glofitamab, mosunetuzumab — emerging options in multiply relapsed NHL; off-the-shelf, no manufacturing delay[23]
- Hodgkin: ABVD, escalated BEACOPP, BV-AVD; pembrolizumab/nivolumab (highly active — PD-L1 amplification at 9p24.1)[24][25]
- MCL: ibrutinib, acalabrutinib, zanubrutinib, venetoclax, brexucabtagene (KTE-X19 CAR-T)[26]
Palliative Procedures
- Dexamethasone (4–16 mg daily): Lymphoma tumor control — even in end-stage disease, steroids can dramatically reduce lymphoma bulk and B symptoms; one of the most powerful comfort interventions[27]
- Rituximab palliative single agent: Can reduce lymphoma bulk and B symptoms in CD20+ disease with minimal toxicity — worth discussing even in hospice context[28]
- Palliative radiation: Even low-dose 2×2 Gy can palliate bulky disease; highly effective for localized painful or obstructing lymphoma[29]
- SVC syndrome intervention: Stent placement or emergent radiation — comfort decision even in hospice-eligible patients[30]
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
Lymphoma is unique among cancers referred to hospice: even at multiple relapse, some patients have real, evidence-based curative or significantly life-extending options. The hospice clinician must understand these — not to push treatment, but to ensure no patient is enrolled in hospice without a complete understanding of what remains available.[4][22]
- 01DLBCL at first relapse, chemosensitive, ECOG 0–1: CAR-T cell therapy (axi-cel, tisa-cel, liso-cel) is the preferred option. Curative intent is real — ~40% achieve long-term remission. This conversation belongs at hospice enrollment if CAR-T has not yet been pursued and patient has adequate functional reserve.[4][22]
- 02
- 03Follicular lymphoma progression requiring re-treatment, ECOG 0–2: Multiple effective options with meaningful QoL and OS benefit. Rituximab-based combinations, lenalidomide + rituximab, CAR-T for relapse after ≥2 lines.[31]
- 04Bispecific antibodies (epcoritamab, mosunetuzumab): Off-the-shelf, active in multiply relapsed NHL, manageable toxicity profile even in declining patients. No manufacturing delay unlike CAR-T.[23]
- 05Palliative steroids: Dexamethasone 4–16 mg daily can achieve dramatic symptom relief — B symptom control, tumor bulk reduction, functional restoration. Appropriate even in purely comfort-focused goals.[27]
- 06Palliative rituximab (CD20+ disease): Single-agent, minimal toxicity, can reduce tumor burden and B symptoms. Worth considering even in hospice — discuss with oncology.[28]
- 07Palliative radiation for obstructing or painful bulky lymphoma: Even low-dose (2×2 Gy) achieves response rates >80%. Hospice-compatible comfort intervention.[29]
- 08Patient goals explicitly include life-prolongation: A well-informed patient who understands prognosis and chooses active treatment should receive it without judgment. Ensure full prognosis understanding first.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Lymphoma hospice referral is complicated by the fact that new treatments keep emerging — bispecific antibodies, novel CAR-T constructs, clinical trials. Families often arrive believing another option exists. The clinician must know when treatment has genuinely been exhausted and communicate that clearly without dismissing the family's hope.[5]
- 01
- 02Double-hit/triple-hit lymphoma progression through DA-EPOCH-R and CAR-T: Highest-risk DLBCL subtype. Minimal response to salvage after CAR-T failure. Median OS measured in weeks to months.[9]
- 03ECOG ≥3: No evidence of survival benefit from chemotherapy. Steroids and rituximab may still be appropriate for comfort but not disease modification.[33]
- 04Richter transformation refractory to CHOP-based therapy and CAR-T: Median OS <6 months. The transformation from CLL to aggressive lymphoma marks a prognostic cliff.[10]
- 05T-cell lymphoma progression through multiple lines: Response rates <20% to most salvage regimens. No established curative salvage for most subtypes.[34]
- 06Estimated survival <3 months: Hospice enrollment is appropriate, beneficial, and guideline-supported. All thresholds above converge here.[35]
- 07Patient goals shift explicitly to comfort and presence: When a fully informed patient prioritizes quality over quantity, that is clarity, not defeat.
⚠ The CAR-T aftermath conversation
When a patient has relapsed after CAR-T cell therapy — the treatment that was supposed to be the last option, the one the family was told could cure them — the emotional weight of that conversation is unlike any other in hospice. The family is grieving a specific hope that was specific and real. Name it explicitly. Do not gloss over it. Acknowledge that the hope was real, that the treatment represented the best that medicine could offer, and that the relapse is a loss that deserves to be mourned. Then — and only then — can you redirect to the clinical framework of comfort care.
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Palliative Dexamethasone for Lymphoma Bulk & B Symptoms
Grade ADose: 4–16 mg PO/IV daily; taper to lowest effective dose
Steroids remain one of the most powerful interventions in end-stage lymphoma. Lymphoma cells are exquisitely sensitive to corticosteroids. Dexamethasone 4–16 mg daily can reduce tumor bulk, eliminate B symptoms (fever, night sweats, weight loss), and improve functional status for weeks to months. This is not disease treatment — it is symptom management. It belongs in the comfort kit conversation at enrollment. Taper planning is a primary clinical task — abrupt discontinuation causes rebound B symptoms and possible adrenal insufficiency.[40]
Palliative Rituximab for CD20+ Lymphoma
Grade BDose: Rituximab 375 mg/m² IV every 4 weeks; outpatient infusion
Single-agent rituximab has meaningful response rates in follicular and marginal zone lymphoma even at multiple relapse. Minimal toxicity, outpatient infusion, can reduce lymphadenopathy and B symptoms. Discuss with oncology whether a monthly single-agent infusion is consistent with hospice goals — in many cases it is. Requires CD20+ disease confirmation and adequate venous access.[10]
Low-Dose Palliative Radiation for Bulky Disease
Grade ADose: 2×2 Gy (2 fractions of 2 Gy each) — the LD-RT protocol
Even 2×2 Gy achieves response rates >80% in indolent lymphoma and meaningful palliation in aggressive lymphoma. This is one of the most effective, fastest-acting comfort interventions available in end-stage lymphoma — response occurs within days. Refer to radiation oncology before the obstruction crisis occurs. Particularly effective for painful or obstructing nodal masses. Two treatment visits total.[28][29]
Acupuncture for B Symptom Fatigue, Pain, and Night Sweats
Grade BDose: 2–3 sessions per week for 4 weeks, then maintenance 1×/week
Cancer-related fatigue and night sweats in lymphoma respond to acupuncture in multiple studies. Night sweats specifically are one of the most distressing B symptoms and pharmacologically difficult to manage beyond steroids. Acupuncture provides real, measurable relief in randomized trials. Safe, no drug interactions, well-tolerated even in declining patients.[41][42]
IVIG for Hypogammaglobulinemia Post-CAR-T
Grade BDose: IVIG 400 mg/kg IV every 4 weeks; target IgG >400 mg/dL
B-cell aplasia after CAR-T causes profound hypogammaglobulinemia for months to years. Recurrent infections from IgG <400 mg/dL are preventable with IVIG replacement. This is a comfort intervention that prevents the suffering of recurrent pneumonia and sepsis. Discuss whether to continue in hospice context based on patient goals, infection history, and overall trajectory.[21][22]
Mind-Body/MBSR for Anticipatory Grief and Treatment Exhaustion
Grade BDose: 8-week MBSR program adapted for palliative setting; 20–45 min daily
Lymphoma patients who have been through multiple lines of therapy including CAR-T develop a specific psychological profile — treatment exhaustion, anticipatory grief, and profound loss of trust in the future. Mindfulness-based stress reduction specifically reduces these in oncology populations. Even abbreviated programs show benefit. Can be delivered bedside via audio recordings.[48]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
"Post-CAR-T and post-transplant patients are a unique herbal risk population. B-cell aplasia from CAR-T causes immune deficiency that persists for months to years. Immunostimulant herbs that activate T-cells may trigger cytokine release in this population. Herbs that interact with steroids — which are commonly used for lymphoma symptom control — have amplified effects in this context. I tell families: 'I want to know everything you're giving them — not because I'm going to say no to everything, but because some of these can genuinely hurt someone whose immune system has been rebuilt from scratch.' Review every supplement against the patient's current steroid dose, immune reconstitution status, and platelet count before recommending."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade B | 1 g/day capsule or fresh ginger tea | Nausea from chemotherapy sequelae and systemic disease; particularly useful for post-treatment GI symptoms that persist | Safe at recommended doses; minimal drug interactions; avoid high doses in thrombocytopenic patients (antiplatelet effect) |
| Melatonin | Grade C | 1–5 mg PO at bedtime | Sleep disruption from B symptoms including night sweats and fever; may reduce night sweat frequency in some patients | Minimal drug interactions; safe; may cause morning sedation at higher doses; start low at 1 mg |
| Turmeric / Curcumin | Grade C | 500–1000 mg standardized extract daily | Anti-inflammatory; may reduce treatment-related inflammation and pain | CYP3A4 interaction with ibrutinib, venetoclax, and steroids — flag if on these agents; antiplatelet caution in thrombocytopenic patients (platelets <50K) |
| Ashwagandha | Grade C | 300–600 mg standardized root extract daily | Fatigue and anxiety in cancer patients; some adaptogenic benefit | CYP3A4 interactions; caution in patients receiving immunosuppression post-transplant or for GVHD — may interfere with immunosuppressant levels; thyroid-stimulating — caution in thyroid lymphoma |
🚫 Avoid in This Diagnosis
- Echinacea and all immunostimulant herbs: Absolutely contraindicated post-CAR-T and post-transplant. Stimulating T-cell activation in a patient who has already experienced cytokine release syndrome from CAR-T could trigger immune re-activation. Also contraindicated in GVHD. This is the most critical avoid in lymphoma specifically.
- St. John's Wort: CYP3A4 inducer — destroys ibrutinib, acalabrutinib, venetoclax, brentuximab vedotin, and steroid blood levels. Absolutely contraindicated in any lymphoma patient on or recently discontinued from targeted therapy.
- High-dose fish oil, Ginkgo, Vitamin E >400 IU: Antiplatelet effects. Thrombocytopenia from bone marrow involvement or post-transplant marrow suppression is common in end-stage lymphoma. Anything that impairs platelet function increases bleeding risk.
- Green tea extract >800 mg EGCG: Hepatotoxicity risk at high doses. Also potential immune interaction at high immunomodulatory doses in post-CAR-T patients.
- Black cohosh and phytoestrogen supplements: In lymphoma subtypes with hormonal sensitivity (marginal zone, some T-cell lymphomas), estrogenic activity may stimulate growth.
- Cannabis/THC at high doses in CNS lymphoma patients: Lowers seizure threshold. CNS lymphoma patients have elevated seizure risk. CBD alone is safer in this context; discuss with neuro-oncology before recommending THC.
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
Lymphoma trajectory varies enormously by histologic subtype. Indolent lymphoma (follicular, marginal zone) may follow a waxing-waning course over 5–15 years before reaching end-stage. Aggressive lymphoma (DLBCL, double-hit) can progress from diagnosis to death in months. Hodgkin lymphoma — even at relapse — may respond to checkpoint inhibitors for years. The timeline below describes the general trajectory for aggressive NHL reaching hospice, with annotations for indolent and Hodgkin variants.[2][4]
YRS–
MOS
MOS
Early / Stable / Indolent Disease
- Indolent NHL (follicular, marginal zone) on watch-and-wait or first-line therapy — functionally well; this phase can last 5–15 years with lymphadenopathy that waxes and wanes
- Hodgkin lymphoma achieving complete remission after ABVD or BV-AVD — survivorship phase; late effects (pulmonary fibrosis, cardiac toxicity, secondary malignancies) become dominant
- DLBCL achieving CR after R-CHOP — surveillance period; 60% are cured; 40% will relapse within 2 years
- Palliative care integration is essentially never offered at this stage despite chronic disease burden in indolent NHL
MOS–
1 YR
1 YR
Relapse / Salvage / Transformation
- First relapse of DLBCL or aggressive NHL — salvage chemotherapy, CAR-T evaluation, ASCT consideration; this phase is intensely treatment-focused
- B symptoms often return with relapse; CAR-T manufacturing period (3–4 weeks) is a specific window where bridging therapy is critical
- Hodgkin relapse on brentuximab + checkpoint inhibitor — response rates remain high but patient knows disease is no longer cured
- Follicular transformation to DLBCL — this is the prognostic inflection point; the indolent disease has become aggressive
WKS–
MOS
MOS
Hospice Transition / Preterminal
- Post-CAR-T relapse or refractory to all available lines — ECOG declining; B symptoms persistent despite steroids; massive lymphadenopathy causing compression symptoms
- Airway and SVC risk increasing; hospice enrollment most appropriate at this stage
- The CAR-T aftermath conversation must happen here — this is the most emotionally complex enrollment in lymphoma hospice
- Comfort kit preparation: midazolam for airway emergency, dexamethasone for B symptoms, opioids for pain and dyspnea
DAYS–
WKS
WKS
Active Dying
- Massive lymphadenopathy with possible airway compromise — prepare for stridor and dyspnea with positional worsening
- B symptoms may be continuous drenching sweats and fever; dexamethasone providing partial but inadequate control
- Convert to SQ medications; profound fatigue and somnolence; oral intake minimal
- Caregiver education: night sweat management, airway crisis protocol review, when to call nurse
HRS–
DAYS
DAYS
Final Hours
- Possible sudden airway compromise if mediastinal disease — have midazolam drawn and at bedside
- Cheyne-Stokes breathing; mottling; unresponsive; auditory awareness may persist
- Dexamethasone can be continued SQ for comfort even in final hours if B symptoms are dominant
- Presence is the clinical priority; family support at the bedside
Medications to Anticipate
Symptom-targeted pharmacology for this diagnosis. What to have in the comfort kit, what to titrate first, and what the evidence supports.
Dexamethasone is the most important comfort drug in end-stage lymphoma. It is not an adjunct — it is the foundation. B symptoms (fever, night sweats, weight loss) are driven by cytokine release from lymphoma cells; corticosteroids suppress this directly and also reduce lymphoma tumor bulk. Every medication decision in end-stage lymphoma begins with: is the patient on dexamethasone, and is the dose adequate?[40]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Dexamethasone | Corticosteroid / B Symptoms & Tumor Bulk | 4–16 mg PO/SQ daily | The most important comfort drug in end-stage lymphoma. Reduces tumor bulk, eliminates/reduces fever, night sweats, weight loss. Reduces peri-tumoral edema causing compression. Taper planning is primary clinical task — abrupt discontinuation causes rebound B symptoms and possible adrenal insufficiency. Continue even in final days SQ.[40] |
| Morphine | Opioid / Pain & Dyspnea | 2.5–5 mg PO q4h; 1–2 mg SQ q4h | Pain from massive lymphadenopathy, bony involvement, nerve compression. Dyspnea from mediastinal disease responds to opioids. SQ conversion as oral route fails. ⚠ Caution: Avoid NSAIDs in thrombocytopenic patients |
| Midazolam | Benzodiazepine / Airway Emergency | 5–10 mg SQ PRN | Mediastinal lymphoma can cause sudden airway compromise. Must be drawn, labeled, and at the bedside for any patient with mediastinal disease. Also for terminal agitation. Pre-draw and keep accessible. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | B symptoms and airway risk generate profound anxiety. Also useful for anticipatory nausea and insomnia from night sweats. |
| Haloperidol | Antipsychotic / Nausea & Agitation | 0.5–1 mg PO/SQ q8h | Nausea from disease burden, opioids, and metabolic causes. Also first-line for delirium and terminal agitation. |
| Ondansetron | Antiemetic / Nausea Adjunct | 4–8 mg PO/SQ q8h PRN | Adjunct antiemetic. Useful when haloperidol alone is insufficient. Note: May cause constipation — monitor bowel function |
| Indomethacin | NSAID / B Symptom Fever | 25–50 mg PO TID | First-line for lymphoma-associated paraneoplastic fever. NSAIDs are highly effective for B symptom fever specifically. ⚠ Caution: Contraindicated if platelets <50,000; use acetaminophen instead |
| Acyclovir | Antiviral / HSV-VZV Prophylaxis | 400 mg PO BID | Lymphoma and post-transplant patients at high risk of viral reactivation. Continue as comfort measure to prevent painful herpetic outbreaks. |
| IVIG | Immunoglobulin / Post-CAR-T Hypogammaglobulinemia | 400 mg/kg IV q4wk | If recurrent serious infections from B-cell aplasia post-CAR-T. Discuss whether to continue in hospice based on goals and infection history.[21] |
| Glycopyrrolate | Anticholinergic / Terminal Secretions | 0.2 mg SQ q4h | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Airway & SVC Emergency Protocol
For patients with mediastinal or cervical lymphadenopathy — sudden airway compromise is a real clinical risk. Stridor, progressive dyspnea with positional worsening (worse lying flat), and visible neck vein distension (SVC syndrome) are warning signs that must be assessed at every visit. Midazolam 5–10 mg SQ must be drawn, labeled, and at the bedside. Emergency radiation oncology contact information should be in the care plan for any patient where emergent palliative radiation for airway or SVC syndrome is consistent with their goals. Write the airway crisis protocol in the care plan and review it at every visit.
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Dexamethasone is the most powerful comfort drug — and it is chronically underdosed
Lymphoma cells are corticosteroid-sensitive. 4–16 mg dexamethasone daily can dramatically reduce tumor bulk, eliminate B symptoms, and restore functional status for weeks to months. This is not aggressive treatment — it is aggressive symptom management. Do not hesitate to use it. Do not taper prematurely. If your lymphoma patient has B symptoms and is not on dexamethasone, the question is not whether to start it — the question is what dose.
2
B symptoms are clinically manageable — do not accept them as inevitable
Drenching night sweats, persistent fever, and profound weight loss define B symptoms. Dexamethasone, NSAIDs (indomethacin 25–50 mg TID for fever), and in CD20+ disease palliative rituximab can control these symptoms. Assess B symptoms with the same rigor you apply to pain and treat them with the same urgency.
3
Mediastinal disease = airway emergency in slow motion
Assess respiratory status at every visit. Ask about positional dyspnea (worse lying flat = mediastinal compression). Examine neck veins and face for SVC syndrome signs (facial swelling, neck vein distension, upper extremity edema). Have the airway crisis plan written before you need it. Midazolam at the bedside.
4
Post-CAR-T hypogammaglobulinemia is a treatable vulnerability
B-cell aplasia from CAR-T causes IgG deficiency that persists for months to years. Patients at risk of recurrent serious infections from encapsulated bacteria, viruses, and opportunistic organisms. If your hospice patient had CAR-T within the past 12–18 months, ask about infection frequency. IVIG is a comfort intervention that prevents suffering.
5
The CAR-T aftermath conversation requires specific language
When a patient relapses after CAR-T, they and their family have lost the thing they were told was their best and last chance. Do not minimize this by immediately pivoting to hospice logistics. Sit with the loss first. Acknowledge explicitly that this was supposed to work, that the hope was real, and that the grief is real. Then and only then can you move to comfort care.
"I had a patient — 34 years old, DLBCL, double-hit. He'd been through R-CHOP, R-ICE, CAR-T. The CAR-T worked for four months. When it came back, the oncologist told his wife there was nothing left. She looked at me at our first visit and said, 'They told us this was the cure.' She wasn't angry. She was broken. I didn't talk about hospice for the first twenty minutes. I just asked her to tell me about the day they went in for the CAR-T infusion. What they hoped for. What the doctor said. She needed someone to hear the whole story before she could hear what came next."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Lymphoma carries a unique psychosocial burden at end of life. Unlike most solid tumors, lymphoma patients have often been through years of treatment with multiple lines of therapy — each representing a new hope and a new disappointment. CAR-T cell therapy introduces a specific grief: the grief of a cure that was promised and didn't hold. Younger Hodgkin patients face the grief of a disease that was supposed to be curable. The hospice team must address these layers deliberately.[47]
Psychological Distress Screening
Depression — Screen Every Patient
Grade BSingle-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.[47]
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Note: Lymphoma patients post-CAR-T have elevated depression rates due to prolonged treatment course and immune-mediated neuropsychiatric effects from prior ICANS (immune effector cell-associated neurotoxicity syndrome)
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously. Faster onset than SSRIs in this population.
- Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
Anxiety & Existential Distress
Grade B- Treatment exhaustion syndrome: Patients who have been through 3–7 lines of therapy develop a specific psychological profile — fear of another relapse, mistrust of good news, inability to hope
- Lorazepam 0.5 mg PRN for acute anxiety episodes — avoid scheduled use unless breakthrough is frequent
- Dignity therapy: Particularly relevant for younger Hodgkin patients facing death from a "curable" cancer — structured life narrative intervention reduces suffering and increases sense of meaning[43]
- Refer to social work and chaplain at enrollment — not at crisis
Spiritual Assessment
Spirituality is not the same as religion. Patients with no religious affiliation still have spiritual needs — meaning, legacy, connection, peace. Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?" This opens spiritual conversation without assuming any tradition.
For some post-CAR-T patients, the failure of cutting-edge medicine creates a profound crisis of faith — in science, in God, in the possibility that anything can be trusted. The chaplain belongs at enrollment, not at the end.
Goals-of-Care Communication
Opening the Conversation
- "What is your understanding of what the CAR-T therapy accomplished?" — critical for post-CAR-T patients
- "What did your oncologist tell you about what options remain?" — assesses illness understanding
- "What are you most hoping for in the time ahead?" — surfaces values
- "If the night sweats and fevers could be controlled, what would matter most to you?" — anchors in achievable comfort
Communication Pitfalls
- Don't say "the CAR-T failed" — say "the lymphoma came back despite the treatment"
- Don't immediately pivot from CAR-T discussion to hospice logistics — sit with the grief first
- Don't frame palliative steroids as "just steroids" — frame as the most powerful tool for their specific symptoms
- Don't assume a young Hodgkin patient's family understands the prognosis — they often believe cure is still possible
Suicidal Ideation & Hastened Death Requests
Passive wish for death ("I'm ready to go") is common and often existentially appropriate — it is not the same as active suicidal ideation. Assessment requires careful distinction: passive wish for death (common, often appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol and conversation). Do not conflate these. Do not avoid the question.
Note: Younger Hodgkin patients (20s-30s) have elevated existential distress and treatment-refractory lymphoma patients have high rates of passive death wishes. Assess at every visit.
Key Psychosocial Angles in Lymphoma
- 01The CAR-T grief: CAR-T is positioned as a potentially curative final option. Families are told 40–50% achieve durable remission. When it relapses, the family has lost not just a treatment but the cure they were promised. Specific acknowledgment required.
- 02Treatment exhaustion and the long lymphoma journey: Patients with indolent NHL may have lived with lymphoma for 5–15 years through multiple lines. Profoundly treatment-fatigued. Give explicit permission to stop fighting.
- 03Histologic transformation grief: For patients with follicular or CLL who transform to aggressive DLBCL — the disease they managed for years has changed into something lethal. Experienced as betrayal by the body.
- 04B symptoms and dignity: Drenching night sweats multiple times per night, persistent fever, profound weight loss — physically and emotionally exhausting. The 3 AM sweat-drenched patient needs B symptom assessment with the same rigor as pain.
- 05Younger Hodgkin patients: 20s and 30s, told this was curable. Specific anger and grief. Legacy work, relationship completion, parenting grief must begin at enrollment.
- 06Spiritual dimension of immune failure: Post-CAR-T patients experienced cutting-edge medicine that didn't work. Crisis of faith in medicine, God, possibility. Chaplain at enrollment.
Clinical Pearl
"The night sweats in lymphoma are not just uncomfortable — they are exhausting in a way that disrupts sleep, strains caregivers who change linens at 3 AM, and relentlessly reminds the patient that the disease is active. Dexamethasone controls them. If your lymphoma patient has B symptoms and is not on dexamethasone, the question is not whether to start it — the question is what dose to start with. Ask at every visit."
"I've sat with patients who were profoundly at peace and patients who were in spiritual agony — and from the outside, you couldn't always tell the difference. The ones in agony weren't always crying. Some of them were very quiet, very polite, very 'I'm fine.' You have to ask. You have to ask directly, you have to sit down, and you have to mean it when you do."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
You are watching someone you love go through something that no one should have to face. Lymphoma at this stage often looks dramatic — you may see large lumps, drenching sweats, and profound exhaustion. We want you to know what to expect, what you can do, and when to call us.
What You May See
- Drenching night sweats — requiring linen/clothing changes multiple times per night. This is the disease causing this, not room temperature. Medication can control it significantly.
- Persistent fever — the disease itself causes fever in lymphoma. The nurse will help distinguish disease-related fever from infection fever. Not every fever is an emergency.
- Enlarged lymph nodes — visible lumps in the neck, armpits, or groin. They may be uncomfortable. Medication can reduce their size and pain significantly.
- Difficulty breathing or swelling of face/neck — possible lymph node pressure on blood vessels or airway. Call the nurse immediately if breathing becomes labored or the face swells.
- Profound fatigue — sleeping 16–20 hours per day. This is the disease, not depression. Rest is appropriate.
- Significant weight loss despite eating — the disease is changing the body's metabolism. Forcing food does not reverse this.
How You Can Help
- Keep extra linens and sleepwear accessible for night sweat changes — change quickly and return to rest without turning on bright lights
- Report new or worsening shortness of breath immediately — especially if worse when lying flat. Call the nurse, not 911, unless the nurse instructs otherwise
- Keep the room cool and air circulating — helps with fever and sweating comfort
- Do not push food — small offerings of favorite foods are enough. Cachexia from lymphoma is metabolic, not starvation
- Know the airway emergency protocol your nurse reviewed — have the emergency medication accessible and know where it is
- Be present for ordinary moments — conversation, music, sitting together. This is what will be remembered
📞 Call the nurse immediately if you see:
Sudden difficulty breathing, stridor (high-pitched breathing sound), or inability to speak normally — call nurse immediately (airway protocol). Face or neck swelling developing rapidly (SVC syndrome) — call nurse immediately. Sudden change in level of consciousness — call nurse. Fever above 103°F with shaking chills and confusion (possible infection) — call nurse.
🙏 You came to this point carrying enormous hope. You went through treatments that were supposed to work and watched them stop working. The hope was not misplaced — it was real. What you are doing now — choosing presence over pursuit, choosing quality over quantity — is not giving up on that hope. It is honoring it. You are still fighting for the person you love. You are just fighting differently now. We are here with you.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Dexamethasone is the most powerful comfort drug you have in end-stage lymphoma. Four to sixteen milligrams daily controls B symptoms, reduces tumor bulk, and can restore functional status for weeks to months. It is not aggressive treatment — it is aggressive symptom management. If your lymphoma patient is drenching their sheets every night and burning with fever and you have not started dexamethasone, that is undertreated B symptoms. Start it. Adjust the dose until the sweats stop or you hit the ceiling. Then plan the taper for long-term maintenance.
- 02B symptoms are a specific symptom complex that requires a specific clinical response. Drenching night sweats, persistent fever, and weight loss are not just "to be expected" in end-stage lymphoma. They are treatable. Assess them with the same rigor you apply to pain — use a symptom scale, ask about frequency, ask about severity, ask about impact on sleep and function. Treat them with the same urgency you would treat uncontrolled pain. Dexamethasone, NSAIDs, and in CD20+ disease palliative rituximab are your tools.
- 03Mediastinal lymphoma and the airway. If your patient has bulky mediastinal disease, you are managing an airway emergency in slow motion. Ask about positional dyspnea at every visit — "Is your breathing worse when you lie flat?" Assess neck veins and facial swelling for SVC syndrome. Have the airway crisis plan written and reviewed with the family before you need it. Midazolam drawn, labeled, at the bedside. Know your radiation oncology contact. This is not theoretical — mediastinal lymphoma obstructs airways, and when it happens it happens fast.
- 04The CAR-T aftermath conversation is the hardest enrollment conversation in lymphoma hospice. The family was told this was the cure. They went through the manufacturing wait, the bridging chemotherapy, the infusion, the cytokine release syndrome, the monitoring — and then it worked for a few months. And then it didn't. When they sit across from you on day one, they don't need your hospice brochure. They need you to acknowledge that this was supposed to work, that the hope was real, and that the grief they are carrying is not irrational. Sit with that before you talk about the plan.
- 05Post-CAR-T hypogammaglobulinemia is a treatable vulnerability that most hospice clinicians don't know about. If your patient had CAR-T within the past year and has had recurrent serious infections — pneumonia, sinusitis, cellulitis — ask about IgG levels. B-cell aplasia from CAR-T causes profound hypogammaglobulinemia that persists for months to years. IVIG replacement prevents the suffering of recurrent infections. Know whether the patient's oncologist has been monitoring this, and whether IVIG is consistent with the patient's goals. It usually is.
- 06Palliative rituximab and palliative radiation belong in the hospice conversation for lymphoma. A monthly rituximab infusion that controls lymphoma bulk and B symptoms in a CD20+ patient is not aggressive treatment — it is symptom management. Two fractions of palliative radiation that shrink a painful or obstructing lymph node mass are not aggressive treatment — they are comfort. These interventions have response rates above 80% in many lymphoma subtypes and they should be on the table at enrollment. Talk to the oncologist and the radiation oncologist. This is what interdisciplinary care looks like.
- 07Histologic transformation changes the prognosis and the conversation fundamentally. When follicular lymphoma or CLL transforms to diffuse large B-cell lymphoma, the patient and family often don't fully understand that they are now facing a categorically different and far more lethal disease. The indolent lymphoma they lived with for years — the one they managed, the one they knew — is gone. Something else has taken its place. Explain this clearly and compassionately. The transformation is not their fault. It was always a possibility inherent in the biology. But the prognosis has changed, and they need to know.
- 08Night sweats at 3 AM are a caregiver crisis, not just a patient symptom. The partner who gets up three times a night to change sheets, help their person change clothes, and then lies awake wondering if the fever means something worse — that partner is being depleted at a rate that is not sustainable. Assess the caregiver separately. Ask: "How are you sleeping? How many times are you up at night?" Address the B symptoms with dexamethasone aggressively — not just for the patient but for the caregiver. Connect the caregiver to respite before they collapse.
- 09Younger Hodgkin patients need legacy work started at enrollment, not in the last week. A 28-year-old dying of Hodgkin lymphoma that was supposed to be curable carries a grief that is specific and raw and unlike what you see in a 72-year-old with a different cancer. Do not treat them the same way. Start the legacy conversation — letters to children, video recordings, memory books — on visit one. Start the relationship completion conversation. If there are young children, the parenting grief conversation must happen early. Social work and chaplain at enrollment. Do not wait.
- 10The steroid taper conversation must happen before enrollment is complete. Lymphoma patients on long-term dexamethasone for symptom control are steroid-dependent. Abrupt discontinuation causes B symptom rebound and possible adrenal insufficiency — both of which will land your patient in the ER, which is the opposite of what hospice is supposed to do. Individualize the taper. The goal is the lowest dose that maintains comfort — not zero. Some patients will be on low-dose dexamethasone until they die, and that is fine. Check the dose at every visit. Ask about B symptoms at every visit. The two are linked.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
2
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858.
3
Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
4
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
5
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma (ZUMA-1). N Engl J Med. 2017;377(26):2531-2544.
6
Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma (ZUMA-7). N Engl J Med. 2022;386(7):640-654.
7
Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation (TRANSFORM). Lancet. 2022;399(10343):2294-2308.
8
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma (JULIET). N Engl J Med. 2019;380(1):45-56.
9
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX). N Engl J Med. 2022;386(4):351-363.
10
Budde LE, Sehn LH, Matasar M, et al. Mosunetuzumab monotherapy in relapsed or refractory follicular lymphoma. Lancet Oncol. 2022;23(8):1055-1065.
11
Thieblemont C, Phillips T, Ghesquières H, et al. Epcoritamab in relapsed or refractory large B-cell lymphoma (EPCORE NHL-1). N Engl J Med. 2023;389(25):2335-2345.
12
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231.
13
Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous HCT (CheckMate 205). J Clin Oncol. 2018;36(14):1428-1439.
14
Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma (ECHELON-1). N Engl J Med. 2018;378(4):331-344.
15
Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with previously untreated Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331-344.
16
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
17
Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.
18
Al-Sawaf O, Zhang C, Tanber M, et al. Venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukaemia. N Engl J Med. 2020;382(14):1390.
19
Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era. J Clin Oncol. 2013;31(26):3272-3278.
20
Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401.
21
Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121-130.
22
Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021;106(4):978-986.
23
Nagle SJ, Woo K, Gergis U, et al. Outcomes of patients with relapsed large B-cell lymphoma who do not reach complete remission with CAR T-cell therapy. Eur J Haematol. 2023;110(2):168-176.
24
Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122.
25
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
26
Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023;21(11):1164-1197.
27
Hoppe RT, Advani RH, Ai WZ, et al. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, Version 1.2024. J Natl Compr Canc Netw. 2023;21(10):1017-1048.
28
Haas RL, Poortmans P, de Jong D, et al. Low-dose radiotherapy (2 × 2 Gy) in the treatment of low-grade lymphomas: an overview of the literature. Strahlenther Onkol. 2003;179(11):781-786.
29
Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457-463.
30
LaCasce AS, Batchelor TT, Armand P. Palliative care for patients with hematologic malignancies: progress, challenges, and future directions. Blood Adv. 2023;7(14):3440-3450.
31
El-Jawahri A, LeBlanc TW, Burns LJ, et al. Palliative care and end-of-life outcomes for patients with lymphoma. J Clin Oncol. 2017;35(7):834-841.
32
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
33
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
34
Sarkozy C, Sehn LH. Management of relapsed/refractory diffuse large B-cell lymphoma. Best Pract Res Clin Haematol. 2018;31(3):209-216.
35
Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498-505.
36
Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055-2063.
37
Mohile NA, Abrey LE, Engert A, et al. Therapy for diffuse large B-cell lymphoma with secondary CNS involvement. Blood. 2019;133(7):655-662.
38
Olszewski AJ, Seijo-Montes S, Engel-Nitz NM, et al. Racial disparities in access to chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma. Blood. 2022;139(14):2104-2107.
39
Al-Hamadani M, Habermann TM, Cerhan JR, et al. Ethnic disparities in lymphoma incidence and survival in the United States. Cancer Causes Control. 2015;26(4):527-534.
40
Britto C, Sharma M, Fradkin M, et al. Steroid response in lymphoma: clinical implications for palliative care. J Pain Symptom Manage. 2021;61(4):e7-e14.
41
Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol. 2013;31(7):952-960.
42
Hershman DL, Unger JM, Greenlee H, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. J Clin Oncol. 2018;36(24):2515-2522.
43
Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005;23(24):5520-5525.
44
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
45
El-Jawahri A, Nelson AM, Gray TF, et al. Palliative and end-of-life care for patients with hematologic malignancies. Cancer. 2021;127(16):2984-2993.
46
Davis MP, Temel JS, Balboni T, Glare P. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med. 2015;4(3):99-121.
47
Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ. Systematic review of psychosocial factors associated with quality of life in adult lymphoma survivors. J Clin Oncol. 2012;30(11):1220-1226.
48
Moshe S, Bates SE, Engstrom PF, et al. Mindfulness-based interventions for people diagnosed with cancer. Cochrane Database Syst Rev. 2021;CD011006.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.